• Home
  • Search Results
  • Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma.

Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma.

Toxicology letters (2014-08-03)
W Mattes, K Davis, E Fabian, J Greenhaw, M Herold, R Looser, W Mellert, S Groeters, H Marxfeld, N Moeller, G Montoya-Parra, A Prokoudine, B van Ravenzwaay, V Strauss, T Walk, H Kamp
ABSTRACT

While conventional parameters used to detect hepatotoxicity in drug safety assessment studies are generally informative, the need remains for parameters that can detect the potential for hepatotoxicity at lower doses and/or at earlier time points. Previous work has shown that metabolite profiling (metabonomics/metabolomics) can detect signals of potential hepatotoxicity in rats treated with doxorubicin at doses that do not elicit hepatotoxicity as monitored with conventional parameters. The current study extended this observation to the question of whether such signals could be detected in rats treated with compounds that can elicit hepatotoxicity in humans (i.e., drug-induced liver injury, DILI) but have not been reported to do so in rats. Nine compounds were selected on the basis of their known DILI potential, with six other compounds chosen as negative for DILI potential. A database of rat plasma metabolite profiles, MetaMap(®)Tox (developed by metanomics GmbH and BASF SE) was used for both metabolite profiles and mode of action (MoA) metabolite signatures for a number of known toxicities. Eight of the nine compounds with DILI potential elicited metabolite profiles that matched with MoA patterns of various rat liver toxicities, including cholestasis, oxidative stress, acetaminophen-type toxicity and peroxisome proliferation. By contrast, only one of the six non-DILI compounds showed a weak match with rat liver toxicity. These results suggest that metabolite profiling may indeed have promise to detect signals of hepatotoxicity in rats treated with compounds having DILI potential.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
D-Mannitol, ≥98%
Sigma-Aldrich
Streptomycin sulfate salt, powder
Sigma-Aldrich
Streptomycin sulfate salt, powder, BioReagent, suitable for cell culture
Supelco
Mannitol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Mannitol, ACS reagent
Supelco
Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Mannitol, meets EP, FCC, USP testing specifications
Sigma-Aldrich
Atropine, ≥99% (TLC), powder
Sigma-Aldrich
D-Mannitol, BioXtra, ≥98% (HPLC)
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Mannitol, suitable for plant cell culture
Sigma-Aldrich
Captopril, ≥98% (HPLC), powder
Mannitol, European Pharmacopoeia (EP) Reference Standard
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Millipore
D-Mannitol, ACS reagent, suitable for microbiology, ≥99.0%
SAFC
Methotrexate
USP
Mannitol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
3′-Azido-3′-deoxythymidine, ≥98% (HPLC)
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Supelco
Streptomycin solution, ~1 mg/mL in 1 mM EDTA, analytical standard
Supelco
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Mannitol, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
Streptomycin sulfate salt, powder, BioXtra, suitable for mouse embryo cell culture
Sigma-Aldrich
6-Propyl-2-thiouracil, enzyme inhibitor
Supelco
Captopril, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Streptomycin sesquisulfate hydrate, VETRANAL®, analytical standard
Streptomycin sulfate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
2-Propylpentanoic acid
USP
Valproic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D-Mannitol, tested according to Ph. Eur.